product name Bromodeoxyuridine (BrdU)
Description: Bromodeoxyuridine (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA, and is used in the detection of proliferating cells. The effect of 5-BrdU on the proliferation was studied in the early phases of dedifferentiation of Nicotiana glauca pith explants grown. It was found to be wholly inhibitory only when given during the first 72 h of culture, this inhibition being reversed by simultaneous addition of either deoxyeytidine or thymidine.
References: Neoplasia. 2008 Aug;10(8):804-16; Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31.
307.1
Formula
C9H11BrN2O5
CAS No.
59-14-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 61 mg/mL (198.6 mM)
Water: <1 mg/mL
Ethanol: 3 mg/mL (9.8 mM)
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19411745
| In Vitro |
In vitro activity: In RG2 rat glioma cells, Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion. In H9 cells and BJ fibroblasts, Bromodeoxyuridine alters the cell cycle profile. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession. Kinase Assay: Cell Assay: Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 µM BrdU for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment. |
|---|---|
| In Vivo | In rat glioma RG2 tumor model, Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression. |
| Animal model | |
| Formulation & Dosage | |
| References | Neoplasia. 2008 Aug;10(8):804-16; Curr Protoc Cytom. 2007 Apr;Chapter 7:Unit7.31. |
